Zinc finger proteins put personalized HIV therapy within reach

July 01, 2008

Penn researchers modify T-cell receptor gene to develop new type of AIDS treatment

PHILADELPHIA - Researchers at the University of Pennsylvania School of Medicine and collaborators are using minute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans.

The Penn researchers and colleagues from Sangamo Biosciences (Nasdaq:SGMO), Richmond, CA, who developed the zinc finger technology, report in an advanced online issue of Nature Biotechnology the first steps towards the goal of using modified T cells from an HIV-infected person for their own treatment. They showed that, using the zinc fingers, they could reduce the viral load of immune-deficient mice transplanted with engineered T cells.

"By inducing mutations in the CCR5 gene using zinc finger proteins, we've reduced the expression of CCR5 surface proteins on T cells, which is necessary for the AIDS virus to enter these immune system cells," explains first author Elena Perez, MD, PhD, Assistant Professor of Pediatrics at Penn. "This approach stops the AIDS virus from entering the T cells because it now has an introduced error into the CCR5 gene."

Some people are born with a mutation on their CCR5 gene and therefore do not have a working CCR5 receptor on the surface of their T cells. These rare individuals are immune to HIV infection and seemingly are not affected by the non-functional CCR5 protein. The zinc finger approach aims to mimic this natural immunity.

Perez performed the research while a postdoctoral fellow in the lab of senior author Carl June, MD, Director of Translational Medicine at the Abramson Family Cancer Research Institute, and a Professor of Pathology and Laboratory Medicine at Penn. Perez is also an attending physician with the Children's Hospital of Philadelphia in the Division of Allergy and Immunology.

Normally, zinc fingers bind to different bases in the DNA sequence to regulate the activity of genes. The zinc fingers used in this experiment were designed to bind to specific DNA sequences in the CCR5 gene. The CCR5 protein is one of the two cell-surface receptors needed for HIV to gain entry into a T cell in order to replicate.

In this study, the zinc finger protein brings a DNA enzyme to the CCR5 gene to cut a portion of its sequence, but due to the repair process a new mutation arises in the CCR5 protein, rendering it non-functional. Without a functional CCR5 protein on the cell's surface, HIV cannot enter, presumably leading to resistance to HIV infection.

The researchers demonstrated this process in cell culture and in a mouse model. For the animal part of the study, the investigators used healthy human CD4 T cells and added DNA that expresses the zinc fingers, which modifies the CCR5 co-receptor. They grew the engineered cells in tissue culture flasks and transferred them into immune-deficient mice infected with HIV. "We followed them over time and showed that those mice that received the zinc-finger-treated cells showed less viral load than controls and improved CD4 counts," says Perez.

The researchers are planning a clinical trial in humans in which T cells from HIV patients would have their CCR5 gene deliberately knocked out. These modified T cells could then be infused back into the patients to re-establish their immune system and decrease their viral load.

University of Pennsylvania School of Medicine

---

---

	Johns Hopkins HIV Guide 2012 by Joel E. Gallant (Author) Based On The Same Award-Winning Content As The Johns Hopkins POC-IT Center Online Database, The Johns Hopkins HIV Guide 2012 Is The Most Up-To-Date HIV Treatment And Management Resource On The Market. Written By Dr. Joel E. Gallant, World Renowned Expert In The Field Of HIV And Infectious Disease, This Concise And Well-Organized Medical Reference Is Broken Down Into Several Modules, Including: Diagnosis And Evaluation, Treatment Options, Resistance And Complications, Prophylaxis And Antiretroviral Drug Summaries. Johns Hopkins HIV Guide 2012 Contains The Most Current, Relevant And Evidence-Based Information On HIV And AIDS. Selected Topics Include: • Antiretroviral Therapy Adverse Effects • HIV Antibody Testing • Important Genotype-Resistant Patterns • Musculoskeletal And...
	INITIATING HIV THERAPY: Timing is critical, controversial A concise synopsis of recent research data and current guidelines on when to initiate antiretroviral ... and side effects. (Postgraduate Medicine) by JTE Multimedia Currently available antiretroviral drug regimens are able to suppress HIV replication and allow CD4 recovery in the vast majority of patients with HIV infection. The challenge is to match each patient to the regimen that is most likely to durably suppress HIV replication enough to prevent resistance selection without causing treatment-limiting toxicities. It is also critical, but difficult, to know when to begin treatment relative to CD4 cell count and plasma viral load. In this article, Dr Volberding addresses the central questions surrounding antiretroviral treatment initiation and reviews some available treatment options. Original Publication Date: February 2004
	In HIV therapy adherence, almost isn't good enough.(Clinical Rounds): An article from: Skin & Allergy News by Michele G. Sullivan (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on May 1, 2005. The length of the article is 488 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: In HIV therapy adherence, almost isn't good enough.(Clinical Rounds) Author: Michele G. Sullivan Publication: Skin & Allergy News (Magazine/Journal) Date: May 1, 2005 Publisher: International Medical News Group Volume: 36 Issue: 5 Page: 44(1) Distributed by Thomson...
	Algorithm: Prophylactic Therapies for Adults With HIV Infection (Postgraduate Medicine) by JTE Multimedia Abstract: National Institutes of Health. Department of Health and Human Services. Guidelines for prevention and treatment of opportunistic infections in HIV–infected adults and adolescents. June 18, 2008. www.aidsinfo.nih.gov. Accessed October 5, 2008. Original Publication Date: November 2008
	HIV-ASSOCIATED METABOLIC AND MORPHOLOGIC ABNORMALITY SYNDROME: Welcome therapy may have unwelcome effects (Postgraduate Medicine) by JTE Multimedia Recently, the remarkable progress of medical science in treatment of HIV and AIDS has been found to have a price tag attached. Physicians are encountering a litany of heretofore-unrecognized metabolic abnormalities and bizarre body-composition changes in patients receiving the antiretroviral therapy that has so greatly improved their lives. In this article, Dr Cohan describes changes that have been reported and identifies potential pathophysiologic mechanisms. In addition, he offers insight into treatment of this syndrome, which is only beginning to be recognized and studied. Cohan GR. HIV-associated metabolic and morphologic abnormality syndrome: welcome therapy may have unwelcome effects. Original Publication Date: April 2000
	Group therapy can improve viral load in HIV.(Infectious Diseases): An article from: Internal Medicine News by Damian McNamara (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on February 15, 2005. The length of the article is 953 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Group therapy can improve viral load in HIV.(Infectious Diseases) Author: Damian McNamara Publication: Internal Medicine News (Magazine/Journal) Date: February 15, 2005 Publisher: International Medical News Group Volume: 38 Issue: 4 Page: 67(1) Distributed by Thomson...
	Once-daily regimens are no match for HIV: mutations provide escape routes.(Clinical Rounds): An article from: Family Practice News by Sherry Boschert (Author) This digital document is an article from Family Practice News, published by International Medical News Group on May 1, 2004. The length of the article is 953 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Once-daily regimens are no match for HIV: mutations provide escape routes.(Clinical Rounds) Author: Sherry Boschert Publication: Family Practice News (Magazine/Journal) Date: May 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 9 Page: 24(2) Distributed by Thomson...
	Long-term drug holidays may help HIV patients: 20-month trial.(Infections Diseases): An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on November 15, 2003. The length of the article is 619 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Long-term drug holidays may help HIV patients: 20-month trial.(Infections Diseases) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: November 15, 2003 Publisher: International Medical News Group Volume: 36 Issue: 22 Page: 23(1) Distributed by Thomson...
	The HIV treatment pendulum.(Editorial): An article from: Internal Medicine News by Diane V. Havlir (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on March 15, 2003. The length of the article is 873 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: The HIV treatment pendulum.(Editorial) Author: Diane V. Havlir Publication: Internal Medicine News (Magazine/Journal) Date: March 15, 2003 Publisher: International Medical News Group Volume: 36 Issue: 6 Page: 10(1) Article Type: Editorial Distributed by Thomson...